Can I Take Omega-3 (EPA/DHA) with CJC-1295?

What Is CJC-1295 Modified GRF and Why Does It Matter for Supplement Interactions?

CJC-1295 modified GRF (also called mod-GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary and drives pulsatile GH secretion. Because it modifies lipid metabolism, IGF-1 production, and platelet-adjacent pathways, any supplement with its own metabolic or hemostatic activity deserves a careful look before combining.

Mechanism of Action

CJC-1295 modified GRF extends the half-life of native GHRH from roughly 7 minutes to approximately 30 minutes by resisting dipeptidyl peptidase IV (DPP-IV) cleavage. The result is a sustained GH pulse lasting 2 to 4 hours per injection. Elevated GH then stimulates hepatic IGF-1 secretion, which drives downstream effects on lipid oxidation, insulin sensitivity, and, in some users, transient changes in triglyceride levels. A 2006 phase 2 trial of CJC-1295 (N=65) published in the Journal of Clinical Endocrinology and Metabolism confirmed dose-dependent IGF-1 increases of 28 to 82% above baseline lasting up to 6 days after a single injection.

503A Compounding Status

CJC-1295 is not FDA-approved as a finished drug product. It is dispensed through 503A compounding pharmacies under a prescriber's order. The FDA's 2024 guidance on peptide compounding placed several GHRH analogues under increased scrutiny, so patients should confirm their pharmacy's current compliance status. FDA guidance on compounded drug products is available at the FDA's compounding page.

Why Supplements Are Not "Automatic Pass"

Compounded peptides receive no formal drug-interaction database entry because they are not reviewed through the standard NDA process. That means Natural Medicines and comparable databases carry no CJC-1295 monograph. Clinicians must reason from mechanism, not from a pre-built interaction table.

How Omega-3 (EPA/DHA) Works and Where It Overlaps with CJC-1295

Omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain polyunsaturated fats that exert three relevant pharmacodynamic effects: triglyceride reduction, platelet inhibition, and modest anti-inflammatory activity through competitive arachidonic acid displacement.

Triglyceride Reduction

The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid (EPA-only, 4 g/day as icosapentaenoic acid ethyl ester) reduced cardiovascular events by 25% relative to placebo, with a mean fasting triglyceride reduction of approximately 19% from baseline. REDUCE-IT data are published in the New England Journal of Medicine. Standard over-the-counter fish oil at 1 to 3 g/day of combined EPA/DHA produces more modest TG reductions of 10 to 15% in hypertriglyceridemic patients.

Platelet Inhibition

EPA and DHA reduce thromboxane A2 synthesis and increase the production of less-potent thromboxane A3, which blunts platelet aggregation. A meta-analysis of 15 randomized controlled trials (total N=1,007) found that fish oil supplementation at doses above 3 g/day of combined EPA/DHA significantly prolonged bleeding time (weighted mean difference approximately 1.7 minutes, P<0.05). That meta-analysis is indexed on PubMed.

Anti-Inflammatory and IGF-1 Adjacent Effects

DHA in particular modulates hepatic lipid metabolism via PPAR-alpha activation. Because CJC-1295-driven IGF-1 elevation also influences hepatic lipid partitioning, there is a theoretical convergence at the liver. No controlled trial has directly studied this combination, but the mechanistic overlap means lipid panels provide useful early signal.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is strictly pharmacodynamic. No evidence suggests that EPA or DHA alters the absorption, distribution, metabolism, or excretion of CJC-1295.

Why Pharmacokinetic Interaction Is Unlikely

CJC-1295 is administered subcutaneously and cleared through proteolytic degradation, not through cytochrome P450 enzymes. Omega-3 fatty acids do have weak CYP3A4-modulatory effects at very high doses, but peptide clearance is protease-driven, not CYP-driven. The two agents simply do not share a metabolic pathway.

The Pharmacodynamic Concerns That Do Apply

Two pharmacodynamic concerns are real and clinically actionable.

First, additive antiplatelet effects. GH itself has been shown to modestly suppress platelet aggregation through nitric oxide pathways. A study in the Journal of Clinical Endocrinology and Metabolism (N=24) found that GH replacement in hypopituitary adults decreased platelet aggregation responses compared to baseline. Combining an agent that raises GH with omega-3 at doses above 3 g/day creates a scenario where two antiplatelet mechanisms operate simultaneously, even if neither is as potent as pharmaceutical antiplatelet agents like clopidogrel.

Second, opposing short-term triglyceride effects. Acute GH elevation transiently increases free fatty acid mobilization from adipose tissue, which the liver can re-esterify into VLDL triglycerides. Omega-3 suppresses hepatic VLDL output. The net result is typically TG-neutral or mildly TG-lowering in most patients, but the combination warrants a baseline fasting lipid panel to confirm the direction of effect in individual patients.

Who Faces the Highest Risk from This Combination?

Most healthy adults using CJC-1295 for body composition or recovery at standard compounded doses (typically 100 to 300 mcg subcutaneous, 3 to 5 nights per week) alongside 1 to 3 g/day of EPA/DHA face low bleeding risk. Certain subgroups need closer attention.

Patients on Concurrent Anticoagulants or Antiplatelets

Patients already taking warfarin, apixaban, rivaroxaban, aspirin, or clopidogrel carry a meaningfully higher risk of bleeding when omega-3 is added at doses above 2 g/day. The American Heart Association's 2019 advisory on omega-3 and cardiovascular disease recommends caution with high-dose fish oil in anticoagulated patients. Adding CJC-1295 on top introduces a third potential contributor to platelet dysfunction and warrants prescriber review before proceeding.

Pre-Surgical Patients

Standard surgical preparation guidelines ask patients to stop fish oil supplementation 5 to 7 days before elective procedures because of antiplatelet effects. Patients on CJC-1295 should inform their surgeon of peptide use, as GH-pathway activity may independently affect wound healing kinetics.

Patients with Hypertriglyceridemia at Baseline

A fasting triglyceride level above 500 mg/dL at baseline is a contraindication to starting most anabolic or GH-stimulating protocols without prior treatment. The Endocrine Society's clinical practice guidelines on hypertriglyceridemia recommend lifestyle modification and pharmacotherapy before adding agents that alter GH or lipid flux.

Adolescents and Individuals Under 18

Age <18 is a contraindication for CJC-1295 use outside of formal clinical trials because of open growth plates and incompletely characterized GH-axis effects. Omega-3 is safe at age-appropriate doses, but the peptide itself should not be prescribed to minors.

Practical Dosing and Timing Guidance

No pharmacokinetic data require time separation between omega-3 and CJC-1295. The subcutaneous injection and the oral supplement are processed through entirely different routes.

Standard Dosing Context

Compounded CJC-1295 modified GRF is most often prescribed at 100 to 300 mcg subcutaneous injection administered before sleep, when endogenous GH pulsatility is highest. It is frequently combined with ipamorelin (a ghrelin mimetic, typically 100 to 300 mcg) to amplify the GH pulse without substantially elevating cortisol or prolactin.

EPA/DHA supplementation at 1 to 2 g/day of combined EPA/DHA is the dose range most commonly used for general cardiovascular health and anti-inflammatory purposes. Doses above 3 g/day are where antiplatelet and triglyceride effects become clinically significant, and where monitoring becomes non-optional.

A Practical Approach for Patients Already Taking Both

The following stepwise framework reflects the clinical reasoning used by the HealthRX medical team when evaluating patients who present already taking both agents. It is not a substitute for individualized prescriber assessment.

1. Confirm the omega-3 dose. Below 3 g/day combined EPA/DHA, standard monitoring applies. At or above 3 g/day, add PT/INR or bleeding-time assessment to the baseline workup.
2. Obtain a fasting lipid panel and CBC at baseline before continuing both agents.
3. Identify concurrent anticoagulant or antiplatelet use. If present, consult the prescribing physician before continuing high-dose omega-3 with CJC-1295.
4. Re-check fasting lipids and CBC at 90 days. Most TG and platelet effects will be apparent by this point.
5. If fasting TG falls below 100 mg/dL or if platelet count drops below 100,000/mcL, pause omega-3 and reassess.
6. In the absence of concerning lab changes, the combination can continue with annual lipid and CBC monitoring.

Monitoring: What Labs to Order and When

A structured monitoring schedule protects patients and provides the clinical documentation needed to continue prescribing compounded peptides responsibly.

Baseline Labs

Before initiating or continuing the combination, order:

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides, non-HDL cholesterol)
• Complete blood count with differential
• Fasting glucose and HbA1c (GH elevation can induce transient insulin resistance)
• IGF-1 level (to confirm peptide activity and avoid supraphysiologic IGF-1)
• If on anticoagulants: PT/INR or anti-Xa level depending on the agent

Follow-Up Labs at 90 Days

Repeat fasting lipid panel and CBC. If IGF-1 was elevated at baseline, recheck to confirm it has not exceeded 300 ng/mL (approximately the upper limit for adults under age 40 on most laboratory reference ranges). The Endocrine Society's acromegaly guidelines use IGF-1 normalization as a treatment target, providing a useful ceiling reference.

Annual Monitoring

Patients stable at 90 days can move to annual fasting lipid panels and CBC, with IGF-1 checked every 6 months. Any new cardiovascular symptom, unexplained bruising, or change in concurrent medications warrants an out-of-cycle lab review.

What Clinicians and Guidelines Say

Formal guidance specifically addressing peptide secretagogues combined with omega-3 does not yet exist in any major society publication. The reasoning must be assembled from adjacent sources.

The American Heart Association states: "Patients who may be at risk for bleeding or who are taking anticoagulant or antiplatelet medications should discuss fish oil use with their health care provider before starting supplementation." That statement appears in the AHA's 2002 dietary guidelines update.

The Endocrine Society's 2006 review of GHRH analogues notes that "GH and IGF-1 promote lipolysis and hepatic lipid flux, which may modulate serum triglyceride levels in both directions depending on baseline metabolic status." This makes individualized lipid monitoring more informative than population-level predictions.

Summary of Evidence Quality

The evidence supporting this interaction assessment comes from multiple levels of the hierarchy.

| Evidence source | Quality | What it tells us | |---|---|---| | REDUCE-IT RCT (N=8,179) | High | EPA at 4 g/day reduces TG and cardiovascular events | | Omega-3 antiplatelet meta-analysis (N=1,007) | Moderate | Above 3 g/day prolongs bleeding time | | CJC-1295 phase 2 trial (N=65) | Moderate | Dose-dependent IGF-1 elevation confirmed | | GH and platelet study (N=24) | Low-moderate | GH elevation modestly reduces platelet aggregation | | CJC-1295 + omega-3 direct combination | None | No controlled data exist; risk is inferred from mechanism |

The absence of direct combination data is the honest answer to the question. All guidance here derives from mechanistic reasoning applied to adjacent evidence. Patients deserve to know that.

Frequently Asked Questions